Congress Moves to Curb Chinese Influence in U.S. Biotech Sector Amidst Health Innovation Concerns

A California biotech company, Complete Genomics, could face exclusion from the U.S. market due to ties with China under new bipartisan legislation. The BIOSECURE Act aims to protect American health data and reduce reliance on China in the medical supply chain. The bill has sparked debate on innovation and national security.

A California biotechnology company that helps doctors detect genetic causes for cancer may face exclusion from the U.S. market due to its ties with China. This highlights the tension between health innovation and a bipartisan Congressional push to counter Beijing's global influence.

Complete Genomics, whose employees analyze genetic samples in San Jose, is affected. Its founder, Radoje Drmanac, expressed frustration over geopolitics interfering with science. The U.S. House recently passed the BIOSECURE Act to prevent federal funds from benefiting companies like Complete Genomics with Chinese connections.

The bill is part of a broader effort to counter China's influence, gaining significant House support before moving to the Senate. Proponents argue it's essential for protecting health data and reducing dependency on China. Opponents worry it will hinder drug development and innovation by banning China-linked companies from collaborating with U.S. firms.

(With inputs from agencies.)